Patents Assigned to Neurotech Pharmaceuticals Co., Ltd.
-
Patent number: 8686185Abstract: The present invention provides an efficient method for mass-producing 2-hydroxy-5-(substituted)phenylalkylamino benzoic acid derivatives represented by specific Chemical formulas or their salts, particularly 2-hydroxy-5-[2-(4-trifluoromethylphenyl)ethylamino]benzoic acid or its salt.Type: GrantFiled: October 30, 2008Date of Patent: April 1, 2014Assignee: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Joo Gwag, Jae Young Cho, Young Ae Lee, Cheng Qiling, Yulian Wu, Li Xing
-
Patent number: 8598383Abstract: The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease.Type: GrantFiled: April 23, 2012Date of Patent: December 3, 2013Assignee: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung-Joo Gwag, Sung-Ig Cho, Jae-Young Cho, Young-Ae Lee, Han-Yeol Byun, Doo-Soon Lim, Ki-Baik Hahm, Young-Bae Kwon, Jin-Hwan Lee, Bok-Seon Yoon, Chun-San An, Keun-Sil Ryu
-
Publication number: 20130316988Abstract: The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease.Type: ApplicationFiled: May 3, 2013Publication date: November 28, 2013Applicant: Neurotech Pharmaceuticals Co., Ltd.Inventor: Neurotech Pharmaceuticals Co., Ltd.
-
Patent number: 8455470Abstract: The present invention relates to a pharmaceutical composition useful for treating or preventing inflammatory disease and cell damage, and a method for treating or preventing inflammatory disease and cell damage. The present invention uses the 2-hydroxybenzoic acid derivative represented by the specific chemical formula or its pharmaceutically acceptable salt. The compound of the present invention is useful for treating or preventing cell damage and inflammatory disease including gastritis, gastric ulcer, pancreatitis, colitis, arthritis, diabetes, arteriosclerosis, nephritis, hepatitis, Alzheimer's disease, Parkinson's disease and Lou Gehrig's disease.Type: GrantFiled: April 13, 2007Date of Patent: June 4, 2013Assignee: Neurotech Pharmaceuticals Co., LtdInventors: Byoung-Joo Gwag, Sung-Ig Cho, Jae-Young Cho, Young-Ae Lee, Han-Yeol Byun, Doo-Soon Lim, Ki-Baik Hahm, Young-Bae Kwon, Jin-Hwan Lee, Bok-Seon Yoon, Chun-San An, Keun-Sil Ryu
-
Publication number: 20120301551Abstract: The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.Type: ApplicationFiled: June 22, 2012Publication date: November 29, 2012Applicant: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Joo GWAG, Young Ae Lee, Jin Hee Shin, Sung Ig Cho, Jae Sung Noh, Jae Young Cho, Ki Won Kim, Hyang Ran Lim, Jae Keun Lee, Han Yeol Byun, Sun Young Ko, Sun Joo Son, Sun Mi Park
-
Patent number: 8211878Abstract: The present invention provides methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death in a patient. The invention includes use of 5-benzylamino salicylic acid (BAS) and its derivatives. Thus, the present invention provides methods for reducing neuronal death in nervous system injuries resulting from amyotrophic lateral sclerosis.Type: GrantFiled: May 24, 2010Date of Patent: July 3, 2012Assignee: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Joo Gwag, Young Ae Lee, Bo Rum Ryu, Sung Hwa Yoon, Ho Sang Moon
-
Patent number: 8211877Abstract: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn2+, and reactive oxygen species. Thus, the present invention provides compositions and methods for treating stroke, traumatic brain and spinal cord injury, epilepsy, and neurodegenerative diseases that are accompanied by severe neuronal loss via excitotoxicity, Zn2+ neurotoxicity, and free radical neurotoxicity.Type: GrantFiled: May 24, 2010Date of Patent: July 3, 2012Assignee: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Joo Gwag, Young Ae Lee, Bo Rum Ryu, Sung Hwa Yoon, Ho Sang Moon
-
Publication number: 20120040939Abstract: The present invention relates to a pharmaceutical composition for treating or preventing stress disorder, depression, anxiety disorder, comprising 5-benzylaminosalicylic acid derivative or its pharmaceutically acceptable salt. The present invention relates to a method for treating or preventing stress disorder, depression, anxiety disorder, comprising 5-benzylaminosalicylic acid derivative or its pharmaceutically acceptable salt.Type: ApplicationFiled: February 9, 2010Publication date: February 16, 2012Applicant: NEUROTECH PHARMACEUTICALS CO., LTD.Inventors: Byoung-Joo Gwag, Sun-Joo Son, Jae-Sung Noh, Jin-Hee Shin
-
Publication number: 20110028757Abstract: The present invention provides an efficient method for mass-producing 2-hydroxy-5-(substituted)phenylalkylaminobenzoic acid derivative represented by the specific Chemical formula or its salt, particularly 2-hydroxy-5-[2-(4-trifluoromethylphenyl)ethylamino] benzoic acid or its salt.Type: ApplicationFiled: October 30, 2008Publication date: February 3, 2011Applicant: NEUROTECH PHARMACEUTICALS CO., LTD.Inventors: Byoung Joo Gwag, Jae Young Cho, Young Ae Lee, Cheng Qiling, Yulian Wu, Li Xing
-
Publication number: 20100331284Abstract: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn2+, and reactive oxygen species. Thus, the present invention provides compositions and methods for treating stroke, traumatic brain and spinal cord injury, epilepsy, and neurodegenerative diseases that are accompanied by severe neuronal loss via excitotoxicity, Zn2+ neurotoxicity, and free radical neurotoxicity.Type: ApplicationFiled: May 24, 2010Publication date: December 30, 2010Applicant: NEUROTECH PHARMACEUTICALS CO., LTD.Inventors: Byoung Joo GWAG, Young Ae Lee, Bo Rum Ryu, Sung Hwa Yoon, Ho Sang Moon
-
Publication number: 20100323995Abstract: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn2+, and reactive oxygen species. Thus, the present invention provides compositions and methods for treating stroke, traumatic brain and spinal cord injury, epilepsy, and neurodegenerative diseases that are accompanied by severe neuronal loss via excitotoxicity, Zn2+ neurotoxicity, and free radical neurotoxicity.Type: ApplicationFiled: May 24, 2010Publication date: December 23, 2010Applicant: NEUROTECH PHARMACEUTICALS CO., LTD.Inventors: Byoung Joo GWAG, Young Ae LEE, Bo Rum RYU, Sung Hwa YOON, Ho Sang MOON
-
Patent number: 7750045Abstract: The present invention provides compositions and methods for prevention and prophylaxis of neurological diseases accompanied by neuronal death. The invention includes synthesis of 5-benzylamino salicylic acid (BAS) and its derivatives. BAS and its derivatives protect cortical neurons from toxic insults by N-methyl-D-aspartate, Zn2+, and reactive oxygen species. Thus, the present invention provides compositions and methods for treating stroke, traumatic brain and spinal cord injury, epilepsy, and neurodegenerative diseases that are accompanied by severe neuronal loss via excitotoxicity, Zn2+ neurotoxicity, and free radical neurotoxicity.Type: GrantFiled: August 17, 2005Date of Patent: July 6, 2010Assignee: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Joo Gwag, Young Ae Lee, Bo Rum Ryu, Sung Hwa Yoon, Ho Sang Moon
-
Patent number: 7608585Abstract: Disclosed is a method for inhibition of necrosis induced by neurotrophin, and more specifically a method for inhibition of necrosis by administrating oxidative stress inhibitor and a method for simultaneous inhibition of necrosis and apoptosis by administrating oxidative stress inhibitor and neurotrophin. The oxidative stress inhibitor of the present invention can inhibit nerve cell necrosis induced by neurotrophin. Moreover, it can be used for protecting nerve cell damage connected with alzheimer disease, parkinson's disease, degenerating cerebropathia and promoting regeneration of the nerve cells by administrating oxidative stress inhibitor and neurotrophin.Type: GrantFiled: January 20, 2004Date of Patent: October 27, 2009Assignee: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Joo Gwag, Sung-Hwa Yoon, Sun-Hee Kim, Seok-Joon Won
-
Publication number: 20090149542Abstract: The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.Type: ApplicationFiled: December 9, 2008Publication date: June 11, 2009Applicant: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Joo GWAG, Young Ae Lee, Jin Hee Shin, Sung Ig Cho, Jae Sung Noh, Jae Young Cho, Ki Won Kim, Hyang Ran Lim, Jae Keun Lee, Han Yeol Byun, Sun Young Ko, Sun Joo Son, Sun Mi Park
-
Patent number: 7422874Abstract: The present invention relates to an expression vector for animal cells. Specifically, the present invention relates to an expression vector, pMS vector, pSG vector and pMSG vector, including the human ?-globin 5? MAR complementary sequence or/and the transcription termination site of the gastrin gene. An expression system using an expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.Type: GrantFiled: July 27, 2001Date of Patent: September 9, 2008Assignees: Mogam Biotechnology Research Institute, Neurotech Pharmaceuticals Co., Ltd.Inventors: Jong-Mook Kim, Jung-Seob Kim, Sun-Mo Oh, Jae-Seung Yoon, Kwang-Hee Baek, Soo-Il Chung, Doo-Hong Park, Yeup Yoon
-
Publication number: 20070298129Abstract: The present invention relates to 2-hydroxy-alkylamino-benzoic acid derivatives and to a combination of cell necrosis inhibitor and lithium, process for the preparation of the derivatives or the combination, pharmaceutical formulation containing the derivatives or the combination, and use of the derivatives or the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The derivatives and the combination of the present invention are useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.Type: ApplicationFiled: May 18, 2007Publication date: December 27, 2007Applicant: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Gwag, Young Lee, Jin Shin, Sung Cho, Jae Noh, Jae Cho, Ki Kim, Hyang Lim, Jae Lee, Han Byun, Sun Ko, Sun Son, Sun Park
-
Publication number: 20070049565Abstract: The present invention relates to a combination of cell necrosis inhibitor and lithium, process for the preparation of the combination, pharmaceutical formulation containing the combination and use of the combination by either concomitant or sequential administration for improvement of treatment of neuronal death or neurological dysfunction. The combination of the present invention shows a synergic effect and thus is useful for treating neurological diseases, such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), Alzheimer's disease, Parkinson's disease, Huntington's disease, stroke, traumatic brain injury or spinal cord injury; and for treating ocular diseases such as glaucoma, diabetic retinopathy or macular degeneration.Type: ApplicationFiled: August 11, 2006Publication date: March 1, 2007Applicant: Neurotech Pharmaceuticals Co., Ltd.Inventors: Byoung Gwag, Young Lee, Jin Shin, Sung Cho, Jae Noh, Jae Cho, Ki Kim, Hyang Lim, Jae Lee, Han Byun